Study of the antiviral activity of Russian anti-influenza agents in cell culture and animal models
- Issue: Vol 55, No 3 (2010)
- Pages: 19-27
- Section: Articles
- Submitted: 09.06.2023
- Published: 15.06.2010
- URL: https://virusjour.crie.ru/jour/article/view/12017
- ID: 12017
Cite item
Full Text
Abstract
The study of the antiviral activity of Russian anti-influenza agents in the cultured MDCK cells demonstrated that arbidol and ribavirin inhibited the reproduction of various influenza A virus strains, including rimantadine- and ozeltamivir-resistant variants, as well as influenza B viruses (IC50 2-8.5 μg/ml). Rimantadine at concentrations of 1-5 μg/ml completely inhibited the reproduction of reference and ozeltamivir-resistant influenza A virus strains, and it had no effect on the reproduction of influenza B viruses and rimantadine-resistant influenza A viruses. Arbidol and ribavirin also inhibited the reproduction of pandemic influenza A/California/04/2009(H1N1), A/California/07/2009(H1N1), and A/Moscow/01/2009(H1N1)swl viruses in the cultured MDCK cells (IC50 = 1.5-4.0 μg/ml) while rimantadine had no effect on their reproduction. The cultured cells showed no significant antiviral activity of ingavirin at nontoxic concentrations (up to 200 μg/ml) against all study strains of influenza A and B viruses, including pandemic A(H1N1) influenza virus strains.
The activity of rimantadine, arbidol, and ingavirin was found on a model of influenza pneumonia in mice infected with their adopted influenza A/Aichi/2/69(H3N2) virus. The preventive efficacy of the three test agents was similar and most pronounced when they were used 96 hours before infection, by preventing 40-50% death in the animals and their body weight loss and by increasing their survival by 1.3-1.5 times. Arbidol and rimantadine were more effective when used for treatment and prophylaxis in doses of 30 and 10 mg/kg/day, respectively, by protecting the infected animals from 60-80% death, increasing their survival by 1.7-2 times, and preventing their body weight loss as compared with the control. The same experiments with ingavirin showed that this agent was less effective than arbidol and rimantadine. Thus, arbidol and rimantadine have a pronounced antiviral infection in both cell culture and a model of influenza pneumonia. The found efficacy of ingavirin on an integral model of murine influenza pneumonia without its activity in the cultured cells is likely to be due to other pharmacological properties of the drug rather than its direct virus-specific action.
The activity of rimantadine, arbidol, and ingavirin was found on a model of influenza pneumonia in mice infected with their adopted influenza A/Aichi/2/69(H3N2) virus. The preventive efficacy of the three test agents was similar and most pronounced when they were used 96 hours before infection, by preventing 40-50% death in the animals and their body weight loss and by increasing their survival by 1.3-1.5 times. Arbidol and rimantadine were more effective when used for treatment and prophylaxis in doses of 30 and 10 mg/kg/day, respectively, by protecting the infected animals from 60-80% death, increasing their survival by 1.7-2 times, and preventing their body weight loss as compared with the control. The same experiments with ingavirin showed that this agent was less effective than arbidol and rimantadine. Thus, arbidol and rimantadine have a pronounced antiviral infection in both cell culture and a model of influenza pneumonia. The found efficacy of ingavirin on an integral model of murine influenza pneumonia without its activity in the cultured cells is likely to be due to other pharmacological properties of the drug rather than its direct virus-specific action.
References
- Бурцева Е. И., Шевченко Е. С., Ленева И. А. и др. Чувствительность к римантадину и арбидолу вирусов гриппа, вызвавших эпидемические подъемы заболеваемости в России в сезоне 2004-2005 г. // Вопр. вирусол. - 2007. - № 2. - С. 24-29.
- Гуськова Т. А., Глушков Р. Г. Арбидол-иммуномодулятор, индуктор интерферона, антиоксидант. - М., 1999. - С. 93.
- Колубухина Л. В., Меркулова Л. Н., Щелканов М. Ю. и др. Эффективность ингавирина при лечении гриппа у взрослых // Тер. арх. - 2009. - Т. 81, № 3. - С. 51-54.
- Ленева И. А., Гуськова Т. А. Арбидол - эффективный препарат для лечения и профилактики гриппа и ОРВИ: обзор результатов клинических исследований // Рус. мед. журн. - 2008. - Т. 16, № 29. - С. 1972-1976.
- Логинова С. Я., Борисевич С. В., Максимов В. А. и др. Изучение лечебной эффективности нового отечественного препарата ингавирина в отношении возбудителя гриппа A(H3N2) // Антибиотики и химиотер. - 2008. - Т. 53, № 7-8. - С. 29-30.
- Логинова С. Я., Борисевич С. В., Лыков М. В. и др. Изучение эффективности ингавирина in vitro в отношении мексиканского пандемического подтипа HINI вируса гриппа A/ штамма A/California/04/2009 и A/штамма A/California/07/ 2009 // Антибиотики и химиотер. - 2009. - Т. 54, № 3- 4. С. 15-20.
- Львов Д. К., Бурцева Е. И., Прилипов А. Г. и др. Изоляция 24.05.2009 и депонирование в Государственную коллекцию вирусов (ГКВ № 2452 от 24.05.2009) первого штамма A/ Moscow/01/2009(H1N1)sw1, подобного свиному вирусу A(H1N1) от первого выявленного 21.05.2009 больного в г. Москве // Вопр. вирусол. - 2009. - Т. 54, № 6. - С. 10- 14.
- Методические указания по изучению специфической противовирусной активности фармакологических веществ: Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ / Под ред. Р. У. Хабриева. - М., 2005. - С. 532-557.
- Романовская А. А., Дурыманов А. М., Шаршов К. А. и др. Изучение чувствительности вирусов гриппа A(H1N1), вызвавших заболевания в апреле-мае 2009 года, к противовирусным препаратам в культуре клеток MDCK // Антибиотики и химиотер. - 2009. - Т. 54, № 5-6. - С. 41-47.
- Assay Guidance Manual. http://www/ncgc.nih.gov/guidance/ section2.html.
- Boriskin Y., Leneva I., Pecheur E. et al. Arbidol: a broad-spectrum antiviral compound that bloks viral fusion // Curr. Med. Chem. - 2008. - Vol. 15. - P. 997-1005.
- Glushkov R. G. Arbidol. Antiviral, immunostimulant, interferon inducer // Drug of the Future. - 1992. - Vol. 17. - P. 1079- 1081.
- Hayden F. WHO guidelines on the use of vaccines and antivirals during influenza. - Annex 5-Considerations for the use of antivirals during an influenza pandemic, Geneva, 2-4 October, 2002.
- Leneva I. A., Russell R. J., Boriskin Y. S. et al. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol // Antiviral Res. - 2009. - Vol. 81. - P. 132-140.
- Monto A. Viral susceptibility and the choice of influenza antivirals // Clin. Infect. Dis. - 2008. - Vol. 47. - P. 346-348.
- Shi L., Xiong H., He J. et al. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo // Arch. Virol. - 2007. - Vol. 152. - P. 1447.
- Update: drug susceptibility of swine-origin influenza A(H1N1) viruses, April 2009. Centers for Disease Control and Prevention (CDC) // MMWR Morb Mortal Wkly Rep. 2009. - Vol. 58. - P. 433-435.
- Wang M., Cai B., Li L. et al. Efficacy and safety of arbidol in treatment of naturally acquired influenza // Zhongguo Yi Xue Ke Xue Yuan Xue Bao. - 2004. - Vol. 26. - P. 289-293.
- Watanabe W., Konno K., Ijichi K. et al. MTT colorimetric assay system for the screening of anti-orthomyxo- and anti-paramyxoviral agents // J. Virol. Meth. - 1994. - Vol. 48, N 2- 3. - P. 257-265.
- Zlydnikov D. M., Kubar O. I., Kovaleva T. P. et al. Study of rimantadine in the USSR: a review of the literature // Rev. Infect. Dis. - 1981. - Vol. 3. - P. 408-421.